Those advantages led to more machines being installed this year, and as a result, greater demand for Illumina's high-margin consumables. NovaSeq is faster, and over time, it could reduce the cost of gene sequencing from $1,000 today to as little as $100. Illumina's systems are used to provide individuals with insight into their genetic makeup, such as a person's ancestry, too. They're also used to match patients up with the medicines most likely to help them. Researchers use gene sequencing machines to identify gene mutations responsible for disease. Illumina Corp.'s ( NASDAQ:ILMN) latest gene sequencing machine, NovaSeq, offers researchers an opportunity for greater genetic insight at a lower cost.
#STOCK MARKET GAIN 2017 FULL#
Efforts to reform Medicaid fell flat in Donald Trump's first full year in office, and that's got investors thinking that any changes to Medicaid that get made won't be as bad as initially feared. Reform that crimps Medicaid enrollment is the company's biggest risk, but that risk has turned out to be the biggest tailwind to its shares in 2017. Centene's focus on Medicaid means it makes less in profit per member than peers selling employer-based plans, so its selling, general, and administrative expenses are lower than those of many competing health insurers. The company still makes most of its money running state Medicaid programs, though, and revenue from that market has climbed significantly following Medicaid expansion in over 30 states. One of the few health insurers to be expanding its presence on the Obamacare health insurance exchanges, Centene Corp's ( NYSE:CNC) shares surged last year as acquisitions expanded it into new counties and states.
0 kommentar(er)
